Breaking News Instant updates and real-time market news.

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

, RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

11:44
11/21/18
11/21
11:44
11/21/18
11:44

Aquestive selloff on generic Suboxone decision overdone, says RBC Capital

RBC Capital analyst Randall Stanicky attributes the added pressure on Aquestive Therapeutics (AQST) shares to yesterday's decision to lift the preliminary injunction on Dr. Reddy's (RDY) launching a generic version of Suboxone. He notes this will impact the milestones that Aquestive receives from Indivior, with the remaining milestones now unlikely. However, he notes that Suboxone in total comprises about $3 per share in value in his model, which is meaningfully less than the two-day selloff of $7 in the stock, which makes the pullback "meaningfully overdone" in his view. Stanicky has an Outperform rating on Aquestive shares with a $24 price target.

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

  • 19

    Jan

AQST Aquestive Therapeutics
$9.60

-3.57 (-27.11%)

08/31/18
BMOC
08/31/18
NO CHANGE
Target $26
BMOC
Outperform
Aquestive Therapeutics' Sympazan approval is major achievement, says BMO Capital
BMO Capital analyst Gary Nachman kept his Outperform rating and $26 price target on Aquestive Therapeutics, saying the tentative approval that it received today for Sympazan to treat Lennox-Gastaut Syndrome is an "important achievement". The analyst notes the decision is validating the company's PharmFilm technology which is "helping set the stage for its commercial build-out in CNS and anticipation for the bigger Libervant opportunity in refractory seizures."
09/12/18
WEDB
09/12/18
INITIATION
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
09/13/18
WEDB
09/13/18
INITIATION
Target $33
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Aquestive Therapeutics with an Outperform rating and $33 price target. The analyst considers Aquestive Therapeutics to be an opportunity to invest in proprietary PharmFilm technology being leveraged to develop a pipeline of 10 drugs and candidates and to provide an oral alternative in patients having difficulty swallowing pills or only having invasive options like injections.
11/19/18
JMPS
11/19/18
NO CHANGE
Target $31
JMPS
Outperform
Aquestive CRL for 'peripheral' program has no read-through, says JMP Securities
After the FDA issued a CRL for Aquestive Therapeutics' tadalafil oral film candidate, JMP Securities analyst Jason Butler said he did not have this "peripheral" product in his valuation for Aquestive shares and he does not believe it is a major focus for investors. The issues raised by FDA appear specific to this product and he does not see any negative read-through to the company's other programs, Butler tells investors. He maintains an Outperform rating and $31 price target on Aquestive shares.
RDY Dr. Reddy's
$36.89

0.41 (1.12%)

03/27/18
EVER
03/27/18
NO CHANGE
Target $155
EVER
Outperform
Evercore sees higher chances of Revlimid patent settlement for Celgene
Evercore ISI analyst Umer Raffat believes the odds of a Revlimid patent settlement between Celgene (CELG) and Dr. Reddy's (RDY) have gone up "considerably" following a recent court filing. The filing, according to the analyst, shows Dr. Reddy's agreed to resolve claims construction issues, which he believes "implies a clear alignment in thought process between both sides." A potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018, and could lead a quick re-rating in the valuation multiple, Raffat tells investors in a research note. He keeps Celgene as his top pick for 2018 with an Outperform rating and $155 price target.
05/29/18
RHCO
05/29/18
NO CHANGE
Target $96
RHCO
Hold
Celgene price target lowered to $96 from $106 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on Celgene (CELG) to $96 after last week's R&D meeting hosted by the management, which "highlighted" the importance of the multiple myeloma program to the company, its research into the mechanism of iMiD drugs, and its pursuit of anti-B-cell maturation antigen in treatment function. The analyst believes that while the company can sustain its position of leadership in myeloma, he is concerned with the overhang on the stock coming from intellectual property litigation on Revlimid, anticipating the stock to remain rangebound until next week's likely generic Revlimid settlement with Dr. Reddy's (RDY).

TODAY'S FREE FLY STORIES

SCL

Stepan Company

$75.84

0.62 (0.82%)

21:26
12/10/18
12/10
21:26
12/10/18
21:26
Initiation
Stepan Company initiated  »

Stepan Company initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

21:25
12/10/18
12/10
21:25
12/10/18
21:25
Conference/Events
Morgan Stanley semiconductors analysts to hold analyst/industry conference call »

U.S. Semiconductors…

POL

PolyOne

$30.74

-0.24 (-0.77%)

21:17
12/10/18
12/10
21:17
12/10/18
21:17
Initiation
PolyOne initiated  »

PolyOne initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLN

Olin

$20.32

0.14 (0.69%)

21:14
12/10/18
12/10
21:14
12/10/18
21:14
Initiation
Olin initiated  »

Olin initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRA

Kraton

$24.26

0.3 (1.25%)

21:07
12/10/18
12/10
21:07
12/10/18
21:07
Initiation
Kraton initiated  »

Kraton initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HT

Hersha Hospitality

$18.49

-0.27 (-1.44%)

20:57
12/10/18
12/10
20:57
12/10/18
20:57
Downgrade
Hersha Hospitality rating change at Wells Fargo »

Hersha Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARS

Cars.com

$23.94

-0.37 (-1.52%)

20:53
12/10/18
12/10
20:53
12/10/18
20:53
Hot Stocks
Cars.com responds to letter from Starboard Value fund »

Cars.com states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERI

Veritone

$6.90

1.28 (22.78%)

20:49
12/10/18
12/10
20:49
12/10/18
20:49
Hot Stocks
Veritone confirms unsolicited bid from Apis Capital »

Veritone confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGVT

Ingevity

$86.46

1.31 (1.54%)

20:47
12/10/18
12/10
20:47
12/10/18
20:47
Initiation
Ingevity initiated at Stifel »

Ingevity initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$41.36

-0.36 (-0.86%)

20:38
12/10/18
12/10
20:38
12/10/18
20:38
Initiation
H.B. Fuller initiated at Stifel »

H.B. Fuller initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$72.77

-0.36 (-0.49%)

20:29
12/10/18
12/10
20:29
12/10/18
20:29
Initiation
Eastman Chemical initiated at Stifel »

Eastman Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$23.04

-1.19 (-4.91%)

20:25
12/10/18
12/10
20:25
12/10/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CE

Celanese

$89.79

-1.445 (-1.58%)

20:24
12/10/18
12/10
20:24
12/10/18
20:24
Initiation
Celanese initiated at Stifel »

Celanese initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASIX

AdvanSix

$25.33

0.18 (0.72%)

20:18
12/10/18
12/10
20:18
12/10/18
20:18
Initiation
AdvanSix initiated at Stifel »

AdvanSix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWW

Grainger

$285.60

-3.88 (-1.34%)

20:11
12/10/18
12/10
20:11
12/10/18
20:11
Initiation
Grainger initiated at Buckingham »

Grainger initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

NFLX

Netflix

$269.80

4.66 (1.76%)

20:00
12/10/18
12/10
20:00
12/10/18
20:00
Initiation
Netflix initiated at DZ Bank »

Netflix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$0.00

(0.00%)

19:12
12/10/18
12/10
19:12
12/10/18
19:12
Periodicals
Vivendi seeks to invest in Trump partner's Indonesia TV unit, Bloomberg says »

Vivendi is seeking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

, GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

19:05
12/10/18
12/10
19:05
12/10/18
19:05
Periodicals
Human rights orgs urge Google to not launch censored app in China, Verge says »

Dozens of human rights…

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 03

    Mar

ASNA

Ascena Retail

$2.73

-0.28 (-9.30%)

, ASPU

Aspen Group

$5.66

-0.14 (-2.41%)

18:59
12/10/18
12/10
18:59
12/10/18
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$2.73

-0.28 (-9.30%)

ASPU

Aspen Group

$5.66

-0.14 (-2.41%)

CARS

Cars.com

$23.94

-0.37 (-1.52%)

TROX

Tronox

$7.05

-0.25 (-3.42%)

CR

Crane

$78.23

-0.99 (-1.25%)

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

CASY

Casey's General Stores

$119.64

-1.78 (-1.47%)

NX

Quanex

$14.05

-0.13 (-0.92%)

CAMP

CalAmp

$17.02

-0.23 (-1.33%)

RARX

RA Pharmaceuticals

$17.58

1.13 (6.87%)

SAEX

SAExploration

$3.33

-0.11 (-3.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

  • 12

    Dec

TROX

Tronox

$7.05

-0.25 (-3.42%)

18:46
12/10/18
12/10
18:46
12/10/18
18:46
Hot Stocks
Tronox CEO discloses purchase of 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGT

Allegiant Travel

$124.89

-1.45 (-1.15%)

18:37
12/10/18
12/10
18:37
12/10/18
18:37
Hot Stocks
Allegiant reports November total systems traffic up 10.1% »

Reports total systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$108.55

2.85 (2.70%)

18:27
12/10/18
12/10
18:27
12/10/18
18:27
Periodicals
Splunk CEO says customers can now talk via voice-enabled assistants, CNBC says »

Splunk president and CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 19

    Dec

  • 20

    Dec

  • 09

    Jan

EFC

Ellington Financial

$15.57

0.01 (0.06%)

18:22
12/10/18
12/10
18:22
12/10/18
18:22
Hot Stocks
Ellington Financial reports book value per share of $19.37 as of Nov. 30th »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

18:22
12/10/18
12/10
18:22
12/10/18
18:22
Periodicals
New 'Smash Bros.' fastest selling Switch game so far, Gamesindustry.biz says »

Nintendo's latest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

, GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

18:15
12/10/18
12/10
18:15
12/10/18
18:15
Periodicals
Google CEO supports privacy law, denies political bias, Bloomberg says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.